Savvy Advisors Inc. Has $7.36 Million Holdings in Eli Lilly and Company $LLY

Savvy Advisors Inc. grew its holdings in Eli Lilly and Company (NYSE:LLY) by 40.0% during the 3rd quarter, Holdings Channel reports. The firm owned 9,648 shares of the company’s stock after purchasing an additional 2,759 shares during the period. Savvy Advisors Inc.’s holdings in Eli Lilly and Company were worth $7,362,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Vanguard Group Inc. raised its position in shares of Eli Lilly and Company by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock valued at $62,680,004,000 after acquiring an additional 1,183,038 shares during the last quarter. Laurel Wealth Advisors LLC boosted its position in shares of Eli Lilly and Company by 78,621.2% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock worth $9,005,392,000 after purchasing an additional 11,537,661 shares during the last quarter. Norges Bank bought a new position in shares of Eli Lilly and Company in the 2nd quarter worth $8,827,714,000. Jennison Associates LLC grew its stake in shares of Eli Lilly and Company by 4.3% during the second quarter. Jennison Associates LLC now owns 5,447,636 shares of the company’s stock worth $4,246,596,000 after purchasing an additional 226,620 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its holdings in Eli Lilly and Company by 2.0% in the second quarter. Charles Schwab Investment Management Inc. now owns 5,359,653 shares of the company’s stock valued at $4,178,010,000 after purchasing an additional 103,119 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. CICC Research raised their target price on Eli Lilly and Company from $801.00 to $1,060.00 and gave the stock a “neutral” rating in a report on Thursday, November 13th. Cantor Fitzgerald increased their price target on shares of Eli Lilly and Company from $985.00 to $1,205.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th. Wells Fargo & Company lifted their price objective on shares of Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Berenberg Bank boosted their price objective on shares of Eli Lilly and Company from $830.00 to $950.00 and gave the company a “hold” rating in a report on Tuesday, December 2nd. Finally, Leerink Partners upped their target price on shares of Eli Lilly and Company from $1,234.00 to $1,296.00 and gave the company an “outperform” rating in a research note on Thursday, February 5th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $1,217.71.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly agreed to acquire Orna Therapeutics for up to $2.4 billion, expanding its in‑vivo CAR‑T and circular RNA capabilities and diversifying beyond GLP‑1s — a strategic, long‑term pipeline bet. Article Title
• Positive Sentiment: Clinical progress: Lilly reported advancement of solbinsiran in high‑risk cholesterol studies and moved eloralintide into Phase 3, broadening non‑GLP therapeutic opportunities. These data/catalysts can support future revenue streams. Article Title Article Title
• Positive Sentiment: Institutional support: Fisher Asset Management increased its LLY stake, and the Baron Opportunity Fund cited Lilly (driven by Zepbound) as a contributor — signs of investor conviction. Article Title Article Title
• Positive Sentiment: Analyst upgrade: Freedom Capital raised Lilly to a “strong‑buy” (reported via Zacks), which can support sentiment and buying interest. Article Title
• Neutral Sentiment: Macro/market coverage: Multiple pieces assess Lilly vs Novo Nordisk in the large weight‑loss market (potentially ~$100B). These explain market opportunity and competitive dynamics but don’t change fundamentals by themselves. Article Title
• Neutral Sentiment: Partnerships and R&D collaborations (e.g., with gene‑editing start‑ups) continue to expand Lilly’s discovery engine; important longer‑term but incremental near term. Article Title
• Neutral Sentiment: Local growth: Huntsville council set to vote on a Lilly development — could support manufacturing/ops expansion if approved, but is a localized item. Article Title
• Negative Sentiment: Competitive pressure: Novo Nordisk plans packaging/format moves (selling obesity shot in vials) that mirror Lilly’s strategies — a sign competition is intensifying, which could pressure pricing and market share over time. Article Title

Eli Lilly and Company Price Performance

NYSE LLY opened at $1,015.48 on Thursday. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. The stock has a market cap of $960.02 billion, a price-to-earnings ratio of 44.25, a PEG ratio of 0.94 and a beta of 0.39. The business has a 50 day simple moving average of $1,051.24 and a 200 day simple moving average of $903.76. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. The firm had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 112.50%. The business’s revenue was up 42.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 26.14%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.